If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
82
results.
Updated on
15/07/2026 [08:12:00]
Results 50 to 75 of 82
Absstract of: US20260165622A1
0000 This disclosure relates to a glucose-sensing electrode including a nanoporous metal layer and an electrolyte ion-blocking layer formed over the nanoporous metal layer. The nanoporous metal layer is capable of oxidizing both glucose and maltose without an enzyme specific to glucose in the glucose-sensing electrode. The electrolyte ion-blocking layer is configured to inhibit Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− from diffusing toward the nanoporous metal layer such that there is a substantial discontinuity of a combined concentration of Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− between over and below the electrolyte ion-blocking layer.
Absstract of: US20260166219A1
0000 A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Absstract of: US20260166225A1
0000 Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a “morsel track” for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.
Absstract of: US20260167932A1
0000 A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.
Absstract of: WO2026123086A1
The present invention relates to a wearable device intended for the field of healthcare, more specifically for the continuous monitoring of vital signs and for the prevention of pressure ulcers, deep vein thrombosis (DVT) and pulmonary embolism (PE) in bedridden patients or patients with reduced mobility. The device comprises a garment equipped with sensors that monitor an electrocardiogram (ECG), respiratory rate, temperature, oximetry, arterial blood pressure, blood leakage, and glucose levels. A system of anatomical air pockets automatically adjusts the pressure in critical areas of the body so as to redistribute the pressure exerted on critical points susceptible to the formation of sores and on points prone to the formation of blood clots.
Absstract of: WO2026126865A1
The present disclosure pertains to a measurement module and a measurement system with which it is possible to achieve highly accurate measurement of glucose levels. This measurement module includes a plurality of sensors to be attached to a human body via electrodes. In the measurement module, a measurement unit inputs RF signals to at least any one of the sensors to measure reflected signals and transmitted signals, and on the basis of these measured signals, outputs glucose calculation information for calculating a glucose level in the human body. The present disclosure is applicable to wearable devices such as smartwatches.
Absstract of: WO2026128361A1
Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Absstract of: US20260166226A1
Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and/or generate a notification, an inquiry, and/or an alert for presentation to a user.
Absstract of: US20260166220A1
0000 Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. Features of the applicator device provide a more reliable, secure and safe insertion process.
Absstract of: US20260166221A1
Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Absstract of: WO2026128809A1
Provided are compositions including a cell or cells that reduce or attenuate hybrid insulin peptide (HIP) formation, for example, a cell or cells that include an insulin gene with a genetic modification in the C-peptide sequence of the insulin gene. Also provided are methods of using the cell or cell to treat autoimmune disorders, such as type 1 diabetes (T1D), and methods of treating autoimmune disorders, such as type 1 diabetes (T1D), including inhibiting or attenuating cathepsin D (CatD) activity, and identifying CatD inhibitors to treat autoimmune disorders, such as type 1 diabetes (T1D).
Absstract of: WO2026123353A1
The present invention belongs to the technical field of medical devices and particularly relates to a dual closed-loop insulin delivery system, use thereof, and a medical product thereof. Disclosed is a dual closed-loop insulin delivery system, specifically comprising a continuous glucose monitoring system, a dual closed-loop control algorithm, an insulin pump, and a specific glucose-responsive insulin analog. The present invention controls blood glucose in a dual closed-loop mode and can achieve a high time-in-range and more stable, safer, and simpler blood glucose control. Moreover, no human intervention is required during the use of the system. The present invention provides a more intelligent and user-friendlier treatment scheme for diabetic patients.
Absstract of: GB2702575A
A skin contact sensor 100 for detecting a biomarker in the interstitial fluid of a user such as a subject’s glucose or hydration levels. The sensor comprises a reusable electronics part and a disposable medical patch. The medical patch comprises a substrate 40 with a plurality of electrodes 60, conductive elements 70 (like tracks) and a contact interface 80. The substrate 40 may have a support member (90, figure 4c) and the contact interface 80 may be non-integral to the substrate 40. The reusable electronics are electrically connected to the medical patch via the contact interface 80 by an electrical connector (30, figure 4c) and removably secured to the medical patch by an adhesive such as double-sided tape. Electrical contact between the electrodes 60 and patient’s skin is provided by a conductive gel which also serves as a medium into which interstitial fluid is extracted during use and can also contain enzymes to aid in target detection. Figure 1a.
Absstract of: WO2025034851A1
Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
Absstract of: EP4759223A1
This invention relates to medical devices, particularly a continuous glucose monitoring (CGM) device designed for the diagnosis and monitoring of metabolic diseases such as diabetes. The invention offers an innovative monitoring solution for both type 1 diabetes, which arises from insufficient insulin production, and the more common type 2 diabetes, which is associated with insulin resistance. By enabling continuous blood sugar monitoring, the invention provides a user-friendly, eco-friendly, and cost-effective solution for diabetes management. The device allows real-time monitoring of glucose levels and delivers visual, auditory, and vibrational alerts to the user. As a result, it establishes a safer, more practical, and continuous health management system for users.
Absstract of: US20260159864A1
0000 A standardized plant extract is produced by cultivating undifferentiated or differentiated in vitro cultures of Haberlea rhodopensis Friv. (HR), followed by harvesting the biomass and extracting bioactive compounds and primary and secondary metabolites, including organic acids, fatty acids, amino acids, sterols, free phenols, sugars, and polyphenols. The extraction process is performed under controlled conditions to yield an extract with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract. The extract may be combined with glycerol to form a composition with standardized myconoside content. The resulting extract or biomass is then incorporated into products for the pharmaceutical, cosmetic, or food industries. This method provides a consistent, renewable, and sustainable source of raw material, eliminating dependence on wild plant populations and seasonality, and delivers valuable health-protective properties.
Absstract of: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Absstract of: US20260158171A1
The disclosure provides insulin-glucagon-like peptide 1 (GLP-1) polynucleotides for delivery to pancreatic islet cells, as well as compositions comprising the polynucleotides and methods of treating obesity-associated metabolic disorders.
Absstract of: US20260157662A1
The device for dynamic determination of a slow insulin dose to be injected comprises: a means (21) of acquiring multiple blood glucose levels during a first day and the day following the first day,a means (26) of calculating the difference in blood glucose levels,a means (22, 24, 25, 42, 43) of determining if a predetermined event has occurred between going to bed and getting up,a means (26) of determining, if no predetermined event has occurred, a hyperglycaemia or a hypoglycaemia depending on the difference in blood glucose levels,a means (26) of determining if at least a predetermined number of hyperglycaemias or hypoglycaemias have occurred in a predetermined period of time,a means (26) of modifying the slow insulin to be injected, in this case of an occurrence, anda means (25) of indicating a numerical value of the modified slow insulin dose to be injected.
Absstract of: WO2026119866A1
The present invention relates to a computer-implemented method for predicting a risk for a subject to experience an analyte concentration in a bodily fluid above a predetermined glucose event threshold at the end of a predetermined predicting time interval, a data processing system, a computer program, a system, and remote control. The disclosure, thus, relates to the management of diabetes. The risk is predicted based on a plurality of input parameters and using a machine learning model.
Absstract of: US20260158217A1
A diabetes management system including a wearable device having an elongated support patch with an adhesive disposed on a skin side, a sensor portion disposed on a non-skin side and including an electrochemical glucose sensor and a wireless communication module, and a medication delivery portion disposed on a non-skin side and comprising a medication reservoir and a medication pump. The system also includes a behavior tracking device having a tracking wireless communication module, a portable electronic device configured to communicate wirelessly to the wearable device and the behavior tracking device, and a controller. The sensor portion is configured to detect a glucose level of a subject and the controller is configured to receive the glucose level and to transmit to the medication pump an instruction which causes the medication pump to deliver a dose to the subject of a medication based on the glucose level.
Absstract of: US20260157702A1
0000 Control device (30) for determining an amount of carbohydrate (RC) recommendation. The control device comprises a retrieving unit (32), the retrieving unit (32) being configured to retrieve user data, an outlier unit (34), the outlier unit (34) being configured to determine whether a user data is considered to be an outlier or not, an RC unit (36), the RC unit (36) being configured to estimate an RC recommendation using mathematical functions of the user data; and a transmission unit (38), the transmission unit (38) being configured to transmit the RC recommendation. The transmission unit (38) is configured to transmit the RC recommendation if and only if the last user data is not considered to be an outlier.
Absstract of: US20260157664A1
The blood glucose measuring device includes a processor and a memory storing instructions, wherein the instructions, when executed by the processor, cause the blood glucose measuring device to obtain, via a first receiver, a plurality of reflection signals, which is a plurality of lights output from the light source, and obtain, via a second receiver, a plurality of transmission signals, determine, for each of the plurality of reflection signals and each of the plurality of transmission signals, a slope efficiency, which represents a ratio of an output change to an input change of the blood glucose measuring device, determine first analysis data based on the slope efficiency of the plurality of reflection signals and/or second analysis data based on the slope efficiency of the plurality of transmission signals, and determine a final blood glucose value based on at least one of the first analysis data or the second analysis data.
Absstract of: WO2026120503A1
The technology provides a system and method for assessing loss of vibration perception in a subject. It may be useful for the self-diagnosis, self-monitoring and self-treatment of adverse health conditions such as cutaneous neuropathy or diabetic foot, and for developing related prognoses. The system comprises a wearable or handheld vibration device which includes piezoelectric elements. These may be actuated to produce vibrations which are transmitted to the body surface of the subject by a probe. A communications apparatus is provided so that data can be transferred between the vibration device and a computing device such as a smartphone. The computing device is arranged to control levels of intensity of vibration of the piezoelectric elements, to record data representing levels of intensity of vibration, and to record and track input data entered by the user, corresponding to levels of intensity of vibration at which the subject perceives the transmitted vibrations via their body surface.
Nº publicación: WO2026120569A1 11/06/2026
Applicant:
OXIWEAR INC [US]
OXIWEAR, INC.
Absstract of: WO2026120569A1
A system includes a wearable device and a charger case. The wearable device is configured to be positioned on an ear of a wearer, and includes first and second body portions and a connection member mechanically coupled to each of the first body portion and the second body portion. The first body portion and/or the second body portion includes a processor, a memory, and a sensor set including at least one of a pulse oximeter, a photoplethysmogram (PPG) sensor, an accelerometer, a temperature sensor, a proximity sensor, an ambient light sensor, or a gyroscopic sensor. The memory stores instructions to cause the processor to calculate at least one of a blood oxygen saturation level, a pulse rate, a blood pressure level, a blood flow rate, a cardiac output/rhythm, a blood sugar level, a blood carbon monoxide level, a blood nitrous oxide level, or an electrocardiogram of the wearer.
BOPI
Electronic site
